In order to assign an adequate therapy to the BC patient, immunohistochemistry tests for estrogen receptor (ER), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 protein expression are applied to classify BC into different groups [96]. This evidence concerns the gene ERBB2 and breast cancer.